Defeating COVID-19 likely requires both vaccination and targeted treatment for those who contract the virus, says Pfizer.
The drugmaker also says it is testing antiviral protease inhibitors to be administered orally. While anti-vax and pro-ivermectin are calling it a bluff by the company, the latter says it is still a clinical trial.
Pfizer studies have, “demonstrated potent antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as other known coronaviruses.”
“We believe that, if successful and authorized or approved, these investigational therapies could provide end-to-end treatment options for COVID-19 patients.
“They could be used for those exposed to the virus, those with diagnosed infections treated in the outpatient setting, and those hospitalized with moderate to severe infection.”
